European Regulations On Stem Cell Research Help Limit Risks March 25, 2005 By Karen Carey and Anette Breindl
Coley Gets $50M Up Front In ProMune Alliance With Pfizer March 25, 2005 By Karen Carey Coley Pharmaceutical Group Inc. entered a deal with Pfizer Inc. worth up to $505 million for its lead cancer drug, ProMune. (BioWorld Today)Read More
Avastin's Survival Data In NSCLC Sends Genentech Soaring, Again March 16, 2005 By Karen Carey Genentech Inc.'s stock climbed 25 percent in late-day trading Monday after news that a Phase III trial of Avastin met its primary endpoint of survival in non-small-cell lung cancer patients. (BioWorld Today)Read More
